ArticleAAPS PharmSciTech2015
Development and Evaluation of Artesunate-Loaded Chitosan-Coated Lipid Nanocapsule as a Potential Drug Delivery System Against Breast Cancer.
Article in AAPS PharmSciTech, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 68 citations in OpenAlex.
- Development, characterization, and evaluation of the therapeutic efficacy of PEGylated-nanoliposomal artesunate in mice bearing non-small cell lung carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Chitosan-Artesunate nanoparticles: A dual anti-fibrotic and anti-inflammatory strategy for preventing bleb fibrosis post-glaucoma filtration surgery.Drug delivery and translational research · 2025Article
- Lipid-polymer hybrid nanoparticles: a cutting-edge frontier in breast cancer treatment strategies.Nanomedicine (London, England) · 2025Review
- Antibacterial and anti-virulence activity of eco-friendly resveratrol-loaded lipid nanocapsules against methicillin-resistant staphylococcus aureus.Scientific reports · 2025Article
- Development and optimization of raloxifene hydrochloride loaded lipid nanocapsule based hydrogel for transdermal delivery.Therapeutic delivery · 2025Article
- Artesunate-loaded thermosensitive chitosan hydrogel promotes osteogenesis of maxillary tooth extraction through regulating T lymphocytes in type 2 diabetic rats.BMC oral health · 2024Article
- Exosome-drug conjugates delivery: a promising strategy for ameliorating the pharmacokinetic profile of artesunate.Frontiers in bioengineering and biotechnology · 2024Article
- Use of Chitosan as a Precursor for Multiple Applications in Medicinal Chemistry: Recent Significant Contributions.Mini reviews in medicinal chemistry · 2024Review
- Phytochemical Characterization and Efficacy ofPolymers · 2023Article
- Hybrid chitosan-lipid nanoparticles of green tea extract as natural anti-cellulite agent with superiorDrug delivery · 2021Article
- Progress on the study of the anticancer effects of artesunate.Oncology letters · 2021Review
- Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?Frontiers in pharmacology · 2021Review
- Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials.Frontiers in pharmacology · 2020Review
- Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin.Drug delivery · 2019Article
- Nano-engineered lipid-polymer hybrid nanoparticles of fusidic acid: an investigative study on dermatokinetics profile and MRSA-infected burn wound model.Drug delivery and translational research · 2019Article
- Antitumor Research on Artemisinin and Its Bioactive Derivatives.Natural products and bioprospecting · 2018Review
- Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment.BMC cancer · 2017Article
- Design of Drug Delivery Systems Containing Artemisinin and Its Derivatives.Molecules (Basel, Switzerland) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artesunate (ART)--a well-known hydrophobic anti-malarial agent was incorporated in a polymer-lipid hybrid nanocolloidal system for anti-cancer therapeutic. The lipid negatively charged nanoemulsion was formulated by modified hot homogenization method then covered with positively charged chitosan via electrostatic interaction to obtain chitosan-coated lipid nanocapsule (ART-CLN). Physical properties of the system were characterized in terms of size, charge, morphology, drug loading capacity, and physical state. In addition, anti-cancer activities were confirmed by conducting MTT assay for ART and ART-CLN on different cancer cell lines. Obtained ART-CLN after coating chitosan revealed positive charge (13.2 ± 0.87 mV), small particle size (160.9 ± 3.5 nm), and spherical shape. High drug entrapment efficiency (95.49 ± 1.13%) and sustained release pattern were observed. Moreover, the good cellular uptake was recorded by flow cytometry as well as confocal image. Finally, ART-CLN exhibited stronger anti-cancer activity than free ART on breast cancer cell lines (MCF-7, MDA-MB-231). These results suggested that by loading ART into lipid core of polymer-lipid hybrid carrier, the activity and physical stability of ART can be significantly increased for cancer chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.